Skip to main content
Premium Trial:

Request an Annual Quote

ExonHit Licenses Array-Based Toxicity Ranking System to Mitsubishi Pharma

NEW YORK, Sept. 15 (GenomeWeb News) - ExonHit Therapeutics has licensed its microarray-based toxicity evaluation system, Safe-Hit, to Mitsubishi Pharma, the Paris-based company said today.


Safe-Hit allows users to evaluate and rank compounds according to their toxicity. The content of the microarray is based on a library of RNA splicing events specific to toxicity that ExonHit developed using a model of cellular stress. Mitsubishi evaluated the system for one year using its own compounds.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.